Aptinyx’s NYX-2925 Draws Skepticism As It Fails Another Trial
The company is no longer pursuing development of the drug in painful diabetic peripheral neuropathy, but while more optimistic about fibromyalgia, that indication has less supporting data.
You may also be interested in...
Lead candidate NYX-2925 has failed a pair of Phase IIb studies in diabetic peripheral neuropathy and now one in fibromyalgia, leaving Aptinyx’s likely last hopes in neuropsychiatric indications.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Investor unrest expected as Allergan’s NMDA receptor modulator rapastinel fails in Phase III depression program, coming shortly after J&J’s approval in the class with Spravato.